Biosimilar preclinical demand growing as US market beckons, says Harlan
US demand for biosimilar preclinical services is expected to rocket on the back of the US FDA’s acceptance of Sandoz’s biosimilar filing, according to Harlan Laboratories.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs